{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:13:39Z","timestamp":1780582419146,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vemurafenib (VEM) is a commonly used inhibitor of papillary thyroid cancer (PTC) and melanoma with the BRAF<jats:sup><jats:italic>V600E<\/jats:italic><\/jats:sup> mutation; however, acquired resistance is unavoidable. The present study aimed to identify a potential target to reverse resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>A VEM-resistant PTC cell line (B-CPAP\/VR) was established by gradually increasing the drug concentration, and a VEM-resistant BRAF<jats:sup><jats:italic>V600E<\/jats:italic><\/jats:sup> melanoma cell line (A375\/VR) was also established. RNA sequencing and bioinformatics analyses were conducted to identify dysregulated genes and construct a transcription factor (TF) network. The role of a potential TF, forkhead box P2 (FOXP2), verified by qRT-PCR, was selected for further confirmation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The two resistant cell lines were tolerant of VEM and displayed higher migration and colony formation abilities (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). RNA sequencing identified 9177 dysregulated genes in the resistant cell lines, and a TF network consisting of 13 TFs and 44 target genes was constructed. Alterations in FOXP2 expression were determined to be consistent between the two VEM-resistant cell lines. Finally, silencing FOXP2 resulted in an increase in drug sensitivity and significant suppression of the migration and colony formation abilities of the two resistant cell lines (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study successfully established two VEM-resistant cell lines and identified a potential target for VEM-resistant PTC or melanoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-022-03180-y","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T16:03:44Z","timestamp":1667577824000},"page":"86-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Silencing FOXP2 reverses vemurafenib resistance in BRAFV600E mutant papillary thyroid cancer and melanoma cells"],"prefix":"10.1007","volume":"79","author":[{"given":"Suyuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"3180_CR1","doi-asserted-by":"publisher","unstructured":"J. Hu, I.J. Yuan, S. Mirshahidi, A. Simental, S.C. Lee, X. Yuan. Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy. Int. J. Mol. Sci. 22(4), (2021). https:\/\/doi.org\/10.3390\/ijms22041950","DOI":"10.3390\/ijms22041950"},{"issue":"4","key":"3180_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrendo.2016.11","volume":"12","author":"C Romei","year":"2016","unstructured":"C. Romei, R. Ciampi, R. Elisei, A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat. Rev. Endocrinol. 12(4), 192\u2013202 (2016). https:\/\/doi.org\/10.1038\/nrendo.2016.11","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"3180_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7150\/ijms.29935","volume":"16","author":"MI Abdullah","year":"2019","unstructured":"M.I. Abdullah, S.M. Junit, K.L. Ng, J.J. Jayapalan, B. Karikalan, O.H. Hashim, Papillary Thyroid Cancer: Genetic alterations and molecular biomarker investigations. Int J. Med Sci. 16(3), 450\u2013460 (2019). https:\/\/doi.org\/10.7150\/ijms.29935","journal-title":"Int J. Med Sci."},{"issue":"7","key":"3180_CR4","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov, J.A. Fagin, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63(7), 1454\u20131457 (2003)","journal-title":"Cancer Res."},{"issue":"2","key":"3180_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/cancers2020885","volume":"2","author":"RH Grogan","year":"2010","unstructured":"R.H. Grogan, E.J. Mitmaker, O.H. Clark, The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. Cancers (Basel) 2(2), 885\u2013912 (2010). https:\/\/doi.org\/10.3390\/cancers2020885","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3180_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrendo.2011.142","volume":"7","author":"YE Nikiforov","year":"2011","unstructured":"Y.E. Nikiforov, M.N. Nikiforova, Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7(10), 569\u2013580 (2011). https:\/\/doi.org\/10.1038\/nrendo.2011.142","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"3180_CR7","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s00268-016-3534-x","volume":"40","author":"S Fraser","year":"2016","unstructured":"S. Fraser, C. Go, A. Aniss, S. Sidhu, L. Delbridge, D. Learoyd et al. BRAF(V600E) mutation is associated with decreased disease-free survival in papillary thyroid cancer. World J. Surg. 40(7), 1618\u20131624 (2016). https:\/\/doi.org\/10.1007\/s00268-016-3534-x","journal-title":"World J. Surg."},{"issue":"1","key":"3180_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","volume":"33","author":"M Xing","year":"2015","unstructured":"M. Xing, A.S. Alzahrani, K.A. Carson, Y.K. Shong, T.Y. Kim, D. Viola et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J. Clin. Oncol. 33(1), 42\u201350 (2015). https:\/\/doi.org\/10.1200\/JCO.2014.56.8253","journal-title":"J. Clin. Oncol."},{"key":"3180_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-319-91442-8_6","volume":"211","author":"C Garbe","year":"2018","unstructured":"C. Garbe, T.K. Eigentler, Vemurafenib. Recent Results Cancer Res. 211, 77\u201389 (2018). https:\/\/doi.org\/10.1007\/978-3-319-91442-8_6","journal-title":"Recent Results Cancer Res."},{"issue":"10","key":"3180_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1089\/thy.2013.0057","volume":"23","author":"KB Kim","year":"2013","unstructured":"K.B. Kim, M.E. Cabanillas, A.J. Lazar, M.D. Williams, D.L. Sanders, J.L. Ilagan et al. Clinical responses to vemurafenib in patients with metastatic papillary. Thyroid cancer harboring BRAF(V600E) Mutat. Thyroid 23(10), 1277\u20131283 (2013). https:\/\/doi.org\/10.1089\/thy.2013.0057","journal-title":"Thyroid cancer harboring BRAF(V600E) Mutat. Thyroid"},{"issue":"7315","key":"3180_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315), 596\u2013599 (2010). https:\/\/doi.org\/10.1038\/nature09454","journal-title":"Nature"},{"issue":"11","key":"3180_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrd3847","volume":"11","author":"G Bollag","year":"2012","unstructured":"G. Bollag, J. Tsai, J. Zhang, C. Zhang, P. Ibrahim, K. Nolop et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Disco. 11(11), 873\u2013886 (2012). https:\/\/doi.org\/10.1038\/nrd3847","journal-title":"Nat. Rev. Drug Disco."},{"issue":"9","key":"3180_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","volume":"17","author":"MS Brose","year":"2016","unstructured":"M.S. Brose, M.E. Cabanillas, E.E. Cohen, L.J. Wirth, T. Riehl, H. Yue et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17(9), 1272\u20131282 (2016). https:\/\/doi.org\/10.1016\/S1470-2045(16)30166-8","journal-title":"Lancet Oncol."},{"issue":"7","key":"3180_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1634\/theoncologist.2014-0012","volume":"20","author":"JJ Harding","year":"2015","unstructured":"J.J. Harding, F. Catalanotti, R.R. Munhoz, D.T. Cheng, A. Yaqubie, N. Kelly et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist 20(7), 789\u2013797 (2015). https:\/\/doi.org\/10.1634\/theoncologist.2014-0012","journal-title":"Oncologist"},{"key":"3180_CR15","doi-asserted-by":"publisher","unstructured":"F. Crispo, T. Notarangelo, M. Pietrafesa, G. Lettini, G. Storto, A. Sgambato, et al. BRAF inhibitors in thyroid cancer: Clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel) 11(9), (2019). https:\/\/doi.org\/10.3390\/cancers11091388","DOI":"10.3390\/cancers11091388"},{"issue":"40","key":"3180_CR16","doi-asserted-by":"publisher","first-page":"42445","DOI":"10.18632\/oncotarget.6442","volume":"6","author":"M Duquette","year":"2015","unstructured":"M. Duquette, P.M. Sadow, A. Husain, J.N. Sims, Z.A. Antonello, A.H. Fischer et al. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget 6(40), 42445\u201342467 (2015). https:\/\/doi.org\/10.18632\/oncotarget.6442","journal-title":"Oncotarget"},{"issue":"61","key":"3180_CR17","doi-asserted-by":"publisher","first-page":"103207","DOI":"10.18632\/oncotarget.21732","volume":"8","author":"MA Roelli","year":"2017","unstructured":"M.A. Roelli, D. Ruffieux-Daidie, A. Stooss, O. ElMokh, W.A. Phillips, M.S. Dettmer et al. PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors. Oncotarget 8(61), 103207\u2013103222 (2017). https:\/\/doi.org\/10.18632\/oncotarget.21732","journal-title":"Oncotarget"},{"issue":"1","key":"3180_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-019-1110-3","volume":"18","author":"JH Kim","year":"2019","unstructured":"J.H. Kim, J. Hwang, J.H. Jung, H.J. Lee, D.Y. Lee, S.H. Kim, Molecular networks of FOXP family: Dual biologic functions, interplay with other molecules and clinical implications in cancer progression. Mol. Cancer 18(1), 180 (2019). https:\/\/doi.org\/10.1186\/s12943-019-1110-3","journal-title":"Mol. Cancer"},{"key":"3180_CR19","doi-asserted-by":"publisher","first-page":"605025","DOI":"10.3389\/fonc.2021.605025","volume":"11","author":"Y Liu","year":"2021","unstructured":"Y. Liu, T. Chen, M. Guo, Y. Li, Q. Zhang, G. Tan et al. FOXA2-Interacting FOXP2 prevents epithelial-mesenchymal transition of breast cancer cells by stimulating E-Cadherin and PHF2 Transcription. Front Oncol. 11, 605025 (2021). https:\/\/doi.org\/10.3389\/fonc.2021.605025","journal-title":"Front Oncol."},{"issue":"4","key":"3180_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2174\/1568009618666180131115356","volume":"18","author":"J Wu","year":"2018","unstructured":"J. Wu, P. Liu, H. Tang, Z. Shuang, Q. Qiu, L. Zhang et al. FOXP2 promotes tumor proliferation and metastasis by targeting GRP78 in triple-negative breast cancer. Curr. Cancer Drug Targets 18(4), 382\u2013389 (2018). https:\/\/doi.org\/10.2174\/1568009618666180131115356","journal-title":"Curr. Cancer Drug Targets"},{"issue":"8","key":"3180_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s12033-022-00473-5","volume":"64","author":"W Chang","year":"2022","unstructured":"W. Chang, Q. Chang, H. Lu, Y. Li, C. Chen, MiR-221-3p facilitates thyroid cancer cell proliferation and inhibit apoptosis by targeting FOXP2 through hedgehog pathway. Mol. Biotechnol. 64(8), 919\u2013927 (2022). https:\/\/doi.org\/10.1007\/s12033-022-00473-5","journal-title":"Mol. Biotechnol."},{"issue":"3","key":"3180_CR22","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/cam4.2764","volume":"9","author":"J Zhou","year":"2020","unstructured":"J. Zhou, L. Zhang, H. Zheng, W. Ge, Y. Huang, Y. Yan et al. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines. Cancer Med. 9(3), 1115\u20131130 (2020). https:\/\/doi.org\/10.1002\/cam4.2764","journal-title":"Cancer Med."},{"key":"3180_CR23","doi-asserted-by":"publisher","first-page":"510408","DOI":"10.1155\/2014\/510408","volume":"2014","author":"Y Koh","year":"2014","unstructured":"Y. Koh, W.J. Jung, K.S. Ahn, S.S. Yoon, Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a single patient. Biomed. Res. Int. 2014, 510408 (2014). https:\/\/doi.org\/10.1155\/2014\/510408","journal-title":"Biomed. Res. Int."},{"key":"3180_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fonc.2019.00268","volume":"9","author":"SA Luebker","year":"2019","unstructured":"S.A. Luebker, S.A. Koepsell, Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies. Front. Oncol. 9, 268 (2019). https:\/\/doi.org\/10.3389\/fonc.2019.00268","journal-title":"Front. Oncol."},{"issue":"7","key":"3180_CR25","first-page":"3585","volume":"36","author":"H Luo","year":"2016","unstructured":"H. Luo, M. Umebayashi, K. Doi, T. Morisaki, S. Shirasawa, T. Tsunoda,, Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. Anticancer Res 36(7), 3585\u20133589 (2016).","journal-title":"Anticancer Res"},{"issue":"1","key":"3180_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-021-04270-w","volume":"88","author":"N Wang","year":"2021","unstructured":"N. Wang, J. Wen, W. Ren, Y. Wu, C. Deng. Upregulation of TRIB2 by Wnt\/beta-catenin activation in BRAF(V600E) papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib. Cancer Chemother. Pharm. 88(1), 155\u2013164 (2021). https:\/\/doi.org\/10.1007\/s00280-021-04270-w","journal-title":"Cancer Chemother. Pharm."},{"key":"3180_CR27","doi-asserted-by":"publisher","unstructured":"M. Zerfaoui, T.M. Dokunmu, E.A. Toraih, B.M. Rezk, Z.Y. Abd Elmageed, E. Kandil. New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking. Cells 10(2), (2021). https:\/\/doi.org\/10.3390\/cells10020367","DOI":"10.3390\/cells10020367"},{"key":"3180_CR28","doi-asserted-by":"publisher","first-page":"592202","DOI":"10.3389\/fonc.2020.592202","volume":"10","author":"A Porter","year":"2020","unstructured":"A. Porter, D.J. Wong, Perspectives on the treatment of advanced thyroid cancer: Approved therapies, resistance mechanisms, and future directions. Front. Oncol. 10, 592202 (2020). https:\/\/doi.org\/10.3389\/fonc.2020.592202","journal-title":"Front. Oncol."},{"issue":"12","key":"3180_CR29","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/s1357-2725(97)00085-x","volume":"29","author":"DS Latchman","year":"1997","unstructured":"D.S. Latchman, Transcription factors: An overview. Int J. Biochem Cell Biol. 29(12), 1305\u20131312 (1997). https:\/\/doi.org\/10.1016\/s1357-2725(97)00085-x","journal-title":"Int J. Biochem Cell Biol."},{"issue":"6","key":"3180_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3892\/etm.2022.11361","volume":"23","author":"F Yang","year":"2022","unstructured":"F. Yang, Z. Xiao, S. Zhang, FOXP2 regulates thyroid cancer cell proliferation and apoptosis via transcriptional activation of RPS6KA6. Exp. Ther. Med 23(6), 434 (2022). https:\/\/doi.org\/10.3892\/etm.2022.11361","journal-title":"Exp. Ther. Med"},{"issue":"2","key":"3180_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.18388\/abp.2020_5813","volume":"69","author":"R Huang","year":"2022","unstructured":"R. Huang, G. Xiang, X. Duan, H. Wang, K. He, J. Xiao, MiR-132-3p inhibits proliferation, invasion and migration of colorectal cancer cells via down-regulating FOXP2 expression. Acta Biochim Pol. 69(2), 371\u2013377 (2022). https:\/\/doi.org\/10.18388\/abp.2020_5813","journal-title":"Acta Biochim Pol."},{"issue":"33","key":"3180_CR32","doi-asserted-by":"publisher","first-page":"52940","DOI":"10.18632\/oncotarget.9507","volume":"7","author":"KK Wong","year":"2016","unstructured":"K.K. Wong, D.M. Gascoyne, E.J. Soilleux, L. Lyne, H. Spearman, G. Roncador et al. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. Oncotarget 7(33), 52940\u201352956 (2016). https:\/\/doi.org\/10.18632\/oncotarget.9507","journal-title":"Oncotarget"},{"issue":"13","key":"3180_CR33","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.7150\/jca.17407","volume":"8","author":"XL Song","year":"2017","unstructured":"X.L. Song, Y. Tang, X.H. Lei, S.C. Zhao, Z.Q. Wu, miR-618 Inhibits Prostate Cancer Migration and Invasion by Targeting FOXP2. J. Cancer 8(13), 2501\u20132510 (2017). https:\/\/doi.org\/10.7150\/jca.17407","journal-title":"J. Cancer"},{"key":"3180_CR34","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.2147\/OTT.S103682","volume":"9","author":"WZ Jia","year":"2016","unstructured":"W.Z. Jia, T. Yu, Q. An, H. Yang, Z. Zhang, X. Liu et al. MicroRNA-190 regulates FOXP2 genes in human gastric cancer. Onco Targets Ther. 9, 3643\u20133651 (2016). https:\/\/doi.org\/10.2147\/OTT.S103682","journal-title":"Onco Targets Ther."},{"issue":"1\u20133","key":"3180_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0014-5793(02)02976-9","volume":"523","author":"K Hama","year":"2002","unstructured":"K. Hama, K. Bandoh, Y. Kakehi, J. Aoki, H. Arai, Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett. 523(1\u20133), 187\u2013192 (2002). https:\/\/doi.org\/10.1016\/s0014-5793(02)02976-9","journal-title":"FEBS Lett."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03180-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03180-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03180-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T17:36:03Z","timestamp":1672853763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03180-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["3180"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03180-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"19 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}